Michael Hallek Selected Research

idelalisib

6/2022	Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
10/2020	Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial.
1/2020	The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
1/2019	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
1/2019	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
3/2018	CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
1/2018	Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
3/2014	Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Hallek Research Topics

Disease

139	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2022 - 01/2002
98	Neoplasms (Cancer) 04/2022 - 08/2002
23	Infections 08/2022 - 09/2002
21	Leukemia 01/2022 - 08/2002
20	Lymphoma (Lymphomas) 01/2022 - 08/2002
18	Disease Progression 01/2022 - 02/2006
16	Residual Neoplasm 02/2022 - 01/2002
11	Neutropenia 01/2022 - 05/2011
8	COVID-19 10/2022 - 01/2020
8	Hodgkin Disease (Hodgkin's Disease) 08/2022 - 02/2008
8	B-Cell Lymphoma (Lymphoma, B Cell) 02/2022 - 01/2013
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 08/2006
7	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2019 - 03/2009
6	Fatigue 01/2022 - 05/2007
6	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 08/2010
5	Fever (Fevers) 01/2021 - 11/2002
5	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2020 - 01/2012
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 08/2020 - 05/2007
5	Lung Neoplasms (Lung Cancer) 01/2020 - 06/2010
5	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2019 - 12/2014
4	Multiple Myeloma 01/2021 - 03/2006
4	Carcinoma (Carcinomatosis) 10/2018 - 01/2005
4	Inflammation (Inflammations) 01/2017 - 04/2009
3	T-Cell Prolymphocytic Leukemia (Leukemia, T Cell, Chronic) 01/2022 - 06/2013
3	Thrombocytopenia (Thrombopenia) 01/2022 - 11/2002
3	Pneumonia (Pneumonitis) 01/2022 - 01/2012
3	Hemorrhage 01/2022 - 11/2002
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 05/2004
3	Melanoma (Melanoma, Malignant) 01/2020 - 01/2016
3	Pathologic Complete Response 02/2017 - 11/2007
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2017 - 09/2002
3	Carcinogenesis 10/2015 - 01/2013
3	Body Weight (Weight, Body) 01/2011 - 10/2009
2	Atrial Fibrillation 01/2022 - 01/2017
2	Urinary Incontinence 01/2022 - 09/2015
2	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 09/2020
2	Mucositis 01/2021 - 06/2016
2	Tumor Lysis Syndrome 12/2020 - 01/2020

Drug/Important Bio-Agent (IBA)

41	Rituximab (Mabthera)FDA Link 02/2022 - 11/2002
35	fludarabineIBA 01/2022 - 06/2002
27	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2022 - 09/2005
21	ibrutinibIBA 01/2022 - 01/2015
21	venetoclaxIBA 01/2022 - 06/2016
19	obinutuzumabIBA 06/2022 - 03/2014
16	Bendamustine Hydrochloride FDA Link 01/2022 - 09/2011
14	Alemtuzumab (Campath)FDA Link 03/2017 - 01/2002
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2005
12	AntigensIBA 01/2021 - 08/2002
12	LigandsIBA 01/2021 - 03/2006
10	Monoclonal AntibodiesIBA 01/2022 - 08/2002
9	Phosphotransferases (Kinase)IBA 12/2020 - 05/2004
8	idelalisibIBA 06/2022 - 03/2014
8	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 01/2015
8	Biomarkers (Surrogate Marker)IBA 09/2020 - 03/2005
7	Pharmaceutical PreparationsIBA 01/2022 - 10/2010
7	CytokinesIBA 01/2022 - 09/2003
7	AntibodiesIBA 07/2021 - 08/2002
7	Chlorambucil (Leukeran)FDA Link 01/2020 - 10/2009
7	Biological ProductsIBA 11/2019 - 01/2011
6	CD40 Ligand (CD40L)IBA 11/2012 - 09/2002
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2007
5	Lenalidomide (CC 5013)FDA Link 01/2021 - 03/2012
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 07/2010
4	VaccinesIBA 10/2022 - 10/2008
4	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2022 - 02/2015
4	Immunoglobulins (Immunoglobulin)IBA 11/2021 - 09/2003
4	Interleukin-6 (Interleukin 6)IBA 09/2020 - 02/2013
4	Thymidine KinaseIBA 01/2020 - 03/2005
4	ErbB Receptors (EGF Receptor)IBA 10/2019 - 12/2010
4	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 07/2011
3	Prednisone (Sone)FDA LinkGeneric 02/2022 - 02/2015
3	Vincristine (Oncovin)FDA LinkGeneric 02/2022 - 02/2015
3	MicroRNAs (MicroRNA)IBA 01/2022 - 10/2009
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2022 - 04/2011
3	Brentuximab VedotinIBA 01/2021 - 02/2013
3	Macrophage Migration-Inhibitory FactorsIBA 01/2017 - 04/2009
3	HLA Antigens (Human Leukocyte Antigens)IBA 12/2012 - 08/2002
3	src-Family KinasesIBA 08/2008 - 01/2003
3	enhanced green fluorescent proteinIBA 12/2006 - 09/2002
2	COVID-19 VaccinesIBA 10/2022 - 01/2022
2	tirabrutinibIBA 06/2022 - 04/2022
2	RNA (Ribonucleic Acid)IBA 01/2022 - 04/2011
2	Interferon-gamma (Interferon, gamma)IBA 01/2022 - 03/2006
2	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2022
2	acalabrutinibIBA 12/2021 - 01/2021
2	Methotrexate (Mexate)FDA LinkGeneric 06/2021 - 10/2010
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2021 - 09/2005
2	ofatumumab FDA Link 01/2021 - 03/2018
2	Cell-Free Nucleic AcidsIBA 10/2020 - 10/2018
2	Interleukin-10 (Interleukin 10)IBA 09/2020 - 09/2005
2	Interleukin-4 (Interleukin 4)IBA 09/2020 - 11/2012

Therapy/Procedure

66	Therapeutics 04/2022 - 06/2002
32	Drug Therapy (Chemotherapy) 08/2022 - 08/2006
16	Stem Cell Transplantation 01/2018 - 01/2002
11	Hematopoietic Stem Cell Transplantation 01/2019 - 08/2010
9	Immunotherapy 01/2020 - 01/2005
7	Transplantation 06/2021 - 01/2011
5	Palliative Care (Palliative Therapy) 11/2019 - 05/2008
4	Radiotherapy 01/2021 - 07/2008
4	Aftercare (After-Treatment) 01/2021 - 02/2015